Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

digital tools

icons related to iconography inside Cuttsy+Cuttsy branded shapes

Clinical trials explained: Why iconography matters…

Icons serve as a useful form of alternative communication. We spend a lot of time developing icons for healthcare communications. Find out how we use iconography to elevate clinical trial...

Cuttsy + Cuttsy

- PMLiVE

Merck granted FDA approval for Keytruda combination in cervical cancer

The decision marks the third FDA-approved indication for Keytruda in cervical cancer

- PMLiVE

UK national study supports whole genome sequencing in standard cancer care

The trial combined data from the UK’s 100,000 Genomes Project and NHS records

- PMLiVE

Study identifies hundreds of priority targets for cancer drug discovery

Researchers identified 370 priority drug candidates across 27 types of cancer

- PMLiVE

Merck expands cancer immunotherapy pipeline with $680m Harpoon acquisition

The deal includes a T-cell engager for lung cancer and neuroendocrine tumours

- PMLiVE

Pfizer’s Talzenna combination receives EC approval for metastatic prostate cancer

Approximately 470,000 new cases of prostate cancer were reported in Europe in 2020

- PMLiVE

Bristol Myers Squibb’s Opdualag recommended by NICE for advanced melanoma

More than 16,700 new cases of melanoma are diagnosed in the UK every year

- PMLiVE

‘Click chemistry’ system used to map new class of drug targets in cancer and immunology

The novel tagging system won the Nobel Prize in Chemistry in October 2022

- PMLiVE

Johnson & Johnson to acquire ADC specialist Ambrx Biopharma for approximately $2bn

The deal includes an ADC candidate in clinical development to treat advanced prostate cancer

- PMLiVE

Boehringer Ingelheim and 3T announce second cancer immunotherapy partnership

The collaboration brings the potential milestone payments of the agreements to $538.5m

- PMLiVE

Novartis shares positive phase 3 results for Scemblix in chronic myeloid leukaemia

More than 6,300 people are diagnosed with the disease every year in Europe

On a journey to diverse, inclusive, and more efficient rare disease trials

Although orphan drugs represent a sizeable portion of new drug approvals, most rare diseases still lack effective treatment. Even more so than for other conditions, rare disease management contains large care...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links